Accéder au contenu
Merck

Effects of oral hyposensitization therapy with nickel on haemoglobin and haematocrit values in sensitized patients.

International journal of immunopathology and pharmacology (2012-06-16)
A Tammaro, A Narcisi, P P Di Russo, C Abruzzese, C Caperchi, F Persechino, F R Parisella, S Persechino
RÉSUMÉ

Nickel deficiency leads to reduced iron content in organs and to reduced hemoglobin levels and haematocrit counts. We carried out a clinical trial of oral hyposensitization therapy with low doses of nickel on a group of 20 patients affected by systemic allergy to this sensitizer element and with a chronic relapsing low hemoglobin level and haematocrit count. We obtained interesting results on maintaining these values in treated patients.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Nickel(II) sulfate hexahydrate, ACS reagent, ≥98%
Sigma-Aldrich
Nickel(II) sulfate hexahydrate, ReagentPlus®, powder or crystals
Supelco
Nickel(II) sulfate hexahydrate, ≥99.99% trace metals basis
Sigma-Aldrich
Nickel(II) sulfate, anhydrous, 99.99% trace metals basis
Sigma-Aldrich
Nickel(II) sulfate heptahydrate, purum p.a., crystallized, ≥99.0% (KT)
Sigma-Aldrich
Nickel(II) sulfate heptahydrate, 99.999% trace metals basis
Sigma-Aldrich
Nickel(II) sulfate hexa-/ heptahydrate, for nickel plating, DIN 50970 H, ≥20.6% Ni and Co basis